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ABSTRACT
eIF6 is an antiassociation factor that regulates the availability of active 80S. 
Its activation is driven by the RACK1/PKCβ axis, in a mTORc1 independent manner. 
We previously described that eIF6 haploinsufficiency causes a striking survival in 
the Eμ-Myc mouse lymphoma model, with lifespans extended up to 18 months. Here 
we screen for eIF6 expression in human cancers. We show that Malignant Pleural 
Mesothelioma tumors (MPM) and a MPM cell line (REN cells) contain high levels of 
hyperphosphorylated eIF6. Enzastaurin is a PKC beta inhibitor used in clinical trials. 
We prove that Enzastaurin treatment decreases eIF6 phosphorylation rate, but not 
eIF6 protein stability. The growth of REN, in vivo, and metastasis are reduced by 
either Enzastaurin treatment or eIF6 shRNA. Molecular analysis reveals that eIF6 
manipulation affects the metabolic status of malignant mesothelioma cells. Less 
glycolysis and less ATP content are evident in REN cells depleted for eIF6 or treated 
with Enzastaurin (Anti-Warburg effect). We propose that eIF6 is necessary for 
malignant mesothelioma growth, in vivo, and can be targeted by kinase inhibitors.
INTRODUCTION
Protein synthesis (translation) is essential for cell 
growth. It is regulated by ribosome synthesis in the 
nucleolus and ribosome usage in the cytoplasm. Translation 
is deregulated in cancer cells [1, 2]. Recent works have 
shown that the translational machinery plays an active role 
in transformation and tumor malignancy, suggesting that it 
can be a therapeutic target [3, 4]. Furthermore, mutations of 
ribosome-associated factors have been described in sporadic 
cancer, i.e. rpL5 and rpL10 in T-cell acute lymphoblastic 
leukemia [5], stressing the naivety of the simple correlation 
between growth and ribosomal biology.
In eukaryotic cells, the initiation phase of translation 
is rate-limiting for a given mRNA. Throughout initiation, 
Initiation Factors (eIFs) act as regulators, downstream 
of signalling events [6]. Briefly, initiation requires three 
consecutive steps: formation of 43S pre-initiation complex 
through the recruitment of the ternary complex eIF2-
GTP-tRNAi(met) on the small 40S ribosomal subunit; 
formation of 48S by binding of mRNA in complex with 
eIF4F to 43S; recruitment of large 60S subunits and 
formation of elongating 80S. The best-characterized 
oncogenic signalling acting on initiation is driven by 
the PI3K-AKT-mTOR pathway that ultimately regulates 
eIF4F activation and 48S formation [7]. eIF4F comprises 
the cap-binding protein eIF4E, the scaffold protein eIF4G 
and the ATP-dependent helicase eIF4A. eIF4E activity is 
inhibited by dephosphorylated 4E-BPs binding proteins. 
Biochemical, genetic and pharmacological evidences 
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show that either inhibition of 4E-BP activity [8, 9] or 
activation of eIF4E [10, 11] leads to cancer progression. 
mTORc1 complex phosphorylates 4E-BPs. Rapamycin 
and its clinical derivatives (rapalogs) such as everolimus 
are inhibitors of mTORc1 complex. Rapalogs impair 
eIF4F formation and block the growth of sensitive 
tumors. In several contexts, the sensitivity to rapalogs 
depends from the ratio of eIF4E/4E-BPs. Increase in the 
eIF4E/4E-BP ratio attenuates the mTORc1 inhibition 
and viceversa [12–14]. Rapamycin sensitivity can also 
be independent from eIF4E/4E-BP ratio, due to multiple 
mTORc1 substrates [15]. Moreover, the cytostatic effect 
of rapamycin is transient. It was reported that, in different 
tumoral cell lines, 4E-BP1 phosphorylation re-emerges 
after short-term treatment of rapamycin, despite continued 
inhibition of S6K, resulting in a recovery of cap-dependent 
translation [16]. Importantly, the drug is highly effective 
in the presence of PI3K mutations [17]. In contrast, cancer 
cells with mutations in the RAS pathway are resistant to 
mTORc1 inhibition [17], demonstrating the existence of 
either alternative initiation factors or pathways converging 
on translation which control tumor growth.
eIF6 is an initiation factor driven by RACK1-PKCβII 
axis, independently from mTORc1. Mechanistically, 
eIF6 binds 60S ribosomal subunits and has an anti-
association property, by impeding 60S premature joining 
to 40S [18]. Although mostly cytoplasmic, a minor pool 
of eIF6 is essential for nucleolar maturation of 60S 
subunits [19]. In general, eIF6 is rate limiting for tumor 
onset and progression. eIF6 haploinsufficient cells are 
normal, but not efficiently transformed in vitro [20]. In 
a mouse model of Myc-driven lymphomagenesis, eIF6 
heterozygous mice survive much longer, even more than 
one year, when compared to the 4-months life expectancy 
of wt mice [21]. eIF6 phosphorylation of Ser235 has been 
reported in several tumor cells [22]. PKCβII kinase is 
recruited by the scaffold protein RACK1, leading to eIF6 
phosphorylation on Ser235, allowing eIF6 activation [23, 
24]. RACK1/PKC expression confers chemoresistance 
[25]. Consistently, transformed fibroblasts with eIF6S235A 
show resistance to oncogenic transformation and reduced 
growth in vivo [21]. In human cancers, eIF6 is highly 
expressed in colorectal carcinomas, and its overexpression 
is associated with tumor stage [26]. Recently, eIF6 has 
been identified as one of 21 essential genes amplified in 
highly proliferative luminal-subtype human breast cancer 
[27]. Open questions are, i) which tumors rely on eIF6 
expression and/or activation for growth, and ii) how 
feasible and effective is eIF6 targeting.
Malignant pleural mesothelioma (MPM) is 
characterized by an indolent progression with almost 
100% lethality. MPM is generally found to be resistant to 
conventional forms of therapy, such as pemetrexed and 
cisplatinum combination chemotherapy [28]. We recently 
showed that in malignant mesothelioma, translational 
control was altered and by large insensitive to rapamycin 
inhibition, suggesting that other initiation factors can sustain 
tumor growth [29]. This finding was supported by the 
observed ineffectiveness of rapalogs in MPM therapy [30]. 
Here we investigated the hypothesis that eIF6 can be critical 
for MPM growth. We found that eIF6 is overexpressed and 
hyperactivated in mesotheliomas and that inhibition of its 
expression or phosphorylation delays tumor progression.
RESULTS
eIF6 is a marker of aggressive Malignant Pleural 
Mesothelioma (MPM)
To study whether eIF6 protein was expressed in 
malignant pleural mesothelioma (MPM), we performed 
an immunohistochemistry staining on 24 human 
MPM samples from an Italian cohort, using an anti-
eIF6 polyclonal antibody. Of these, 19 were epithelial, 
3 sarcomatous, and 2 biphasic. All MPM cases are 
summarized in Supplementary Table S1. Representative 
stainings of epithelioid and biphasic histotypes of MPM 
are shown in Figure 1A and Supplementary Figure S1. 
Human epithelioid biopsies showed widespread meso-
thelioma infiltration that presented, with different 
prevalence, epithelial and connective components. Tumor 
components were characterized by islands or tubular 
formations. Biphasic (mixed) histotypes showed both 
spindle-shaped cells, typical of sarcomatoid subtype, and 
epithelial areas. In all analyzed cases, eIF6 was expressed 
at high levels both in the nucleoli (black arrows) and in 
the cytoplasm of MPM cells (Figure 1A). Nucleoli were 
enlarged, suggesting abnormal ribosome biogenesis. 
By using calretinin as a diagnostic marker for MPM, 
we confirmed that eIF6 overexpression was limited to 
tumor cells. Conversely, both eIF6 and calretinin are less 
expressed in non-tumoral lung biopsies. (Figure 1A). Next, 
we evaluated both eIF6 expression and phosphorylation 
on human MPM epithelial tumor samples excised. 
These samples were from Glenfield Hospital, Leicester, 
UK. First, we confirmed by Western Blot analysis that 
eIF6 overexpression is a constitutive feature of MPM 
(Figure 1B). Control, non tumoral cells were from primary 
human mesothelium. Second, 2-D electrophoresis on a 
pool of three tumoral samples displayed 3 well-focused 
spots compatible with eIF6 phosphorylation sites. Tumors 
treated with phosphatase showed a single focused spot 
(Figure 1C).
Last, we data-mined eIF6 mRNA levels from MPM 
microarray studies [31]. Data showed that 35/42 MPM 
patient datasets expressed higher levels of eIF6 mRNA 
in tumor samples. However, no relationship between 
eIF6 mRNA levels at time of analysis and survival was 
observed. eIF6 can be phosphorylated by the RAS/
PKC pathway [23]. We data-mined on mesothelioma 
datasets the expression of PKCβ (PRKCB), the favoured 
RACK1 partner [32]. Combined expression of PRKCB 
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Figure 1: eIF6 expression and phoshorylation correlate to lower MPM patients survival. A. IHC stainings on representative human 
non-tumoral samples and on biopsies of epithelial and biphasic malignant pleural mesothelioma: eIF6 expression is evident both in the nucleoli, 
indicated with black arrows, and in the cytoplasm of tumor cells; Calretinin is used as a positive marker of MPM tumors and scale bar is indicated. 
B. Representative Western Blot analysis of different human biopsies of malignant pleural mesothelioma: eIF6 protein levels are higher in tumor 
samples compared to non tumoral ones. eIF6/β-Actin Ratio is quantified by densitometric analysis, as indicated. C. 2-D analysis on a pool of three 
tumor extracts: focused spots are indicated. Treatment with PPase is used as negative control. D. Data mining studies reveal that high co-expression 
of eIF6 and PKCβ is associated to lower survival of MPM patients. Statistical analysis was performed by a paired t-test. p-value ≤ 0.005.
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and eIF6 was then used to evaluate survival. Strikingly, 
high eIF6/high PRKCB expression correlated with lower 
survival, p ≤ 0.005 (Figure 1D). In conclusion, analysis 
of three separate mesothelioma datasets showed that the 
combination of eIF6 expression and phosphorylation 
correlates with negative survival, raising the question 
whether its inhibition may be beneficial.
eIF6 hyperphosphorylation in MPM cell line 
REN
We analyzed the expression and phosphorylation 
of eIF6 in the epithelial MPM cell line, REN, and 
compared it to the expression of eIF6 in non-tumorigenic 
Met-5A mesothelial cells. We observed augmented eIF6 
expression and phosphorylation in REN cells (Figure 2A, 
2B, 2C). Phosphorylation of eIF6 occurs downstream 
of RACK1/PKC activation. PKCβ is the preferential 
partner of RACK1 [23]. Enzastaurin is a specific PKCβ 
inhibitor that has been used in clinical trials for treating 
B-cell malignancies, i.e. [33]. Enzastaurin (1 μM) was 
administered to REN cells, in growing conditions. Cells 
were lysed at 24 hours, 48 hours and 72 hours post-
treatment and the degree of eIF6 phosphorylation was 
analyzed by 2-D electrophoresis, followed by Western 
Blot analysis. Growing REN cells showed 4 well-
focused spots compatible with eIF6 phosphorylation 
state. Cells treated with 1 μM Enzastaurin, up to 48 
hours, showed 3 spots compatible with 1–2 phosphate 
groups. Long-term treatment (72 hours) of Enzastaurin 
augmented dephosphorylation of eIF6. Finally, cell lysates 
treated with phosphatase showed a single focused spot 
(Figure 2D). Enzastaurin does not affect the stability of 
both eIF6 and PKCβ, but the latters are more expressed 
in REN cells compared to non-tumoral Met-5A cells 
(Supplementary Figure S2). It was recently reported that 
Enzastaurin affects the phosphorylation of the downstream 
target of mTORc1 kinase, 4E-BP1, the main mediator of 
cap-dependent translation [34]. However, in MPM both 
4E-BP1 and rpS6 were phosphorylated in the presence of 
Enzastaurin (Figure 2E). In conclusion, the MPM cell line 
REN shows eIF6 PKC-dependent hyperphosphorylation 
and can be used to investigate the effects of eIF6 depletion 
and dephosphorylation on MPM growth.
eIF6 antiassociation activity is important for 
recycling inactive 80S
eIF6 acts in the regulation of translation initiation. 
We performed a methionine incorporation assay and 
polysomal profiles on REN cells, to analyze whether eIF6 
levels affect initiation (Figure 3). We show a representative 
experiment performed on REN cells with either normal 
eIF6 protein levels (control and ShRNA Scramble), 
or reduced ones (ShRNA eIF6). Western Blot analysis 
displays eIF6 protein expression (Figure 3A). Experiments 
were performed 72 hours after lentiviral transduction. 
In summary eIF6 depletion caused a significant protein 
synthesis reduction (Figure 3B) and led to a slight 
decrease of polysomes accompanied by 80S increase, as 
shown in Figure 3C. Since Enzastaurin modulated eIF6 
activity, we performed polysomal profiles and Methionine 
incorporation on REN cells treated with the drug. We 
observed that Enzastaurin caused an increase of 80S peak 
in REN cells but not in Met-5A (Supplementary Figure 
S3A). Enzastaurin inhibited also methionine incorporation 
in REN cells (Supplementary Figure S3B).
Translational inhibition by eIF6 depletion, in vivo, is 
in line with the fact that eIF6 is not strictly necessary for 
translation, but is rate-limiting for oncogene-induced protein 
synthesis [21]. Next, we analysed in an ex-vivo experiment 
the requirement for eIF6 on 80S cancer ribosomes. We 
prepared polysomes extracts from REN cells and added 
recombinant eIF6. Figure 3D shows that eIF6 addition can 
dissociate inactive 80S, as shown by the drop in the 80S 
peak and the increase of free 60S. We recovered all fractions 
derived from polysomal profiles in order to analyze proteins 
distribution by Western Blotting: exogenous eIF6 was 
detected on soluble and 60S fractions, consistent with the 
dissociation data. Taken together our data indicate that eIF6 
activity in cancer cells is necessary for keeping ribosomes 
dissociated, and for initiating new protein synthesis. We 
asked whether this activity is important for tumor growth.
eIF6 reduction and dephosphorylation slow cell 
growth in cultured cells
Established that eIF6 is hyperexpressed and 
hyperphosphorylated in MPM and in the REN cell line, 
we asked whether its depletion or dephosphorylation 
affected growth. We analysed MPM cells growth at 24, 
48 and 72 hours after plating and upon eIF6 depletion 
(Figure 4A, REN cells; Supplementary Figure S4, 
MM98, sarcomatous, MSTO-211H, biphasic). MTT assay 
revealed that the proliferation rate of eIF6 depleted cells 
was slightly reduced compared to the control, in vitro. The 
reduced proliferation was not associated to an increase of 
the apoptotic rate, in REN cells (Supplementary Figure 
S5A). In parallel, we performed a MTT Assay on REN 
cells, treated with 1 μM, 5 μM and 10 μM of Enzastaurin 
and we measured the proliferation rate at the indicated 
time points (Figure 4B). Enzastaurin reduced REN growth, 
indicating its cytostatic effect. The effect was more evident 
in low-serum conditions. eIF6 protein levels were very 
similar at all time points upon Enzastaurin treatment at 
the indicated concentrations (Figure 4C). Furthermore, 
we performed FACS analysis on synchronous REN 
cells, with normal or depleted eIF6 protein levels, and/or 
treated with 1 μM Enzastaurin. Data confirmed that eIF6 
reduction impaired G1/S progression and caused a reduced 
number of cycling cells in G2/M phase. Similar results 
were obtained with Enzastaurin treatment (Supplementary 
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Figure S5). We also quantitated the apoptotic rate of all 
these cells after 72 hours of treatment: we found that the 
percentage of cell death was similar in all considered 
conditions (Supplementary Figure S5). In conclusion, both 
shRNA for eIF6 or Enzastaurin treatment slightly reduce 
proliferation in cultured REN cells, in vitro.
eIF6 depletion and Enzastaurin administration 
have a protective effect, in vivo
Then, we addressed the role of eIF6 activity and 
Enzastaurin, in vivo. We developed a murine MPM model 
by injecting REN cells into immunocompromised NOD-
SCID mice. We injected i.p. 10 millions cells/mouse with 
either wt eIF6 or eIF6 depleted cells. A group of control 
mice was treated with Enzastaurin: administration (75 
mg/Kg) was performed by gavage twice/daily, starting 
at day 7 after injection and suspending it after 5 weeks. 
Mice were sacrificed 60 days after cells injection and 
tumor mass was analyzed. By autopsy, we measured the 
weight of total body, tumor mass, spleen and diaphragm 
and we scored for developed metastasis and hemorrhage. 
Data are summarized in Figure 5A and in Supplementary 
Table S2: mice injected with REN cells depleted of eIF6 
showed reduced tumor mass weight, indicating that the 
amount of eIF6 is a limiting factor for cellular growth, 
in vivo. These mice also revealed less metastasis, since the 
diaphragm weight is reduced. Enzastaurin administration 
provided also a protective effect against tumor growth: 
indeed, tumor mass was strongly reduced, metastasis 
were limited to diaphragm and hemorrhage was mild. 
Both Enzastaurin-treated tumors and shRNA eIF6 tumors 
recovered from NOD-SCID mice showed less CD31 and 
VEGFA-positive cells, indicating reduced angiogenesis 
Figure 2: eIF6 hyperphosphorylation in REN cells is sensitive to Enzastaurin treatment. A. Western Blot analysis shows 
that eIF6 is overexpressed in REN cells compared to non tumorigenic Met-5A cells. B. Real-Time PCR confirms that eIF6 mRNA levels 
are increased in REN cells. C. Representative 2-D gel electrophoresis on REN and Met-5A cells: focused spots indicate that eIF6 is 
hypershosphorylated in REN cells, but not in non tumorigenic Met-5A cells. D. Representative 2-D gel electrophoresis on REN cells 
treated with 1 μM Enzastaurin for 24, 48 and 72 hours: eIF6 phosphorylation is sensitive to Enzastaurin treatment, in a time dependent 
manner. Lambda PPase is used as positive control of unphosphorylation state. E. Representative Western Blot analysis on REN cells treated 
with Enzastaurin at different time points indicates that mTORc1 kinase is activated: phosphorylation of rpS6 and 4E-BP1 are equivalent 
in control cells and upon drug treatment. PP242 treatment is used as control of mTORc1 inactivation. Data are normalized to β-Actin. All 
values represent the mean ± SD. Results are representative of three independent experiments. Asterisks indicate a statistically significant 
change obtained by two-tailed t-test (***p ≤ 0.001).
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Figure 3: eIF6 antiassociation activity modulates the inititiation of translation of REN cells. A. Western Blot analysis 
on REN cells for eIF6 expression in all considered conditions; data are normalized to β-Actin. B. Mean of three independent methionine 
incorporation experiments indicates that eIF6 reduction affects protein synthesis of REN cells. C. Polysomal profiles show that partial 
depletion of eIF6 causes 80S accumulation and reduced translation. 80S/polysomes peaks in each graph are indicated by dashed line. 
D. 5 μg of recombinant biotinylated eIF6 protein is added to polysomes extracts of REN cells: exogenous eIF6 causes the dissociation of 
inactive 80S, in MPM cell line. Western Blot analysis on recovered fractions derived from polysomal profiles exhibits the distribution of 
indicated proteins. Experiments are performed 72 hours post-lentiviral transduction. Data, derived from three independent experiments, are 
represented as mean ± SD. Statistical p-values were calculated by two-tailed t-test, as above (***p ≤ 0.001).
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and close correlation with diminished solid tumor growth 
and metastasis (Figure 5B, Supplementary Figure S6). 
These findings may be in agreement with the protective 
role of eIF6 depletion and/or inactivation by Enzastaurin 
in neo-angiogenesis and metastasis development [35].
Taken together, these data suggest that either 
inhibition of eIF6 expression or eIF6 phosphorylation is 
effective in vivo, and that eIF6 is potentially targetable by 
Enzaustarin.
eIF6 depletion and Enzastaurin cause metabolic 
changes of cancer cells
The protective role of reduced eIF6 and Enzastaurin 
administration in vivo, compared to the modest effects 
on cell growth in vitro raises the question of whether this 
effect could be linked to metabolic changes of tumoral 
REN cells. This selective effect would be consistent with 
the limited effect of eIF6 depletion on basal translation 
[20, 36]. A screening for eIF6-regulated genes in the liver, 
showed eIF6-mediated translation of several transcription 
factors involved in metabolism, resulting in the regulation 
of glycolysis [37]. Here, we show that depletion of eIF6 
by lentiviral ShRNA on REN cells, and Enzastaurin 
treatment led to a reduction of lactate secretion, an 
index of glycolytic flux (Figure 6A). In both cases ATP 
production was significantly reduced in each considered 
time (Figure 6B). In summary eIF6 activity is required for 
a glycolytic switch that may account for its need for tumor 
growth in vivo (Figure 7).
Figure 4: Partial depletion of eIF6 and Enzastaurin treatment affect growth of REN cells. A. Proliferation rate of REN 
cells previously infected with the described lentiviruses is analyzed by MTT Assay. Cells with reduced eIF6 protein levels proliferate less at 
indicated times. B. MTT assay on REN cells treated with 1 μM, 5 μM and 10 μM of Enzastaurin: high doses and long-term treatment with 
Enzastaurin indicate its cytostatic effect, that becomes stronger under serum deprivation. C. Western Blot analysis reveals that Enzastaurin 
does not affect eIF6 protein levels even at high concentrations. All values represent the mean ± SD. Results are representative of three 
independent experiments. Asterisks indicate a statistically significant change obtained by two-tailed Student t-test (*p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001).
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DISCUSSION
We show that eIF6 is highly expressed and activated 
in malignant mesotheliomas, and that inhibition of either 
its activity or phosphorylation reduces tumor burden and 
tumor growth. Our data further establish the deregulation 
of the translational machinery in mesothelioma cells, 
suggesting that this tumor is rather peculiar in its 
capability to sustain translation, being insensitive to 
inhibition of the mTOR pathway [30]. We will discuss our 
Figure 5: Enzastaurin administration and eIF6 depletion have a protective effect, in vivo. A. REN cells with either wt or depleted 
eIF6 protein are injected (i.p.) in NOD-SCID mice. Experimental groups are indicated (control mice n = 3; mice with ShRNA Scramble plus placebo 
n = 7; mice with ShRNA Scramble plus Enzastaurin n = 7; mice with ShRNA eIF6 n = 7). A cohort of control mice was treated with Enzastaurin 
(75 mg/kg) twice daily for 5 weeks. Mice were sacrified two months after tumoral cells injection. eIF6 depletion and Enzastaurin administration reduce 
tumor masses weight and diaphragm metastasis. B. IHC stainings of tumors recovered from NOD-SCID mice. Tissue morphology is evidenced with 
Hematoxylin and Eosin staining; eIF6 is overexpressed both in the nucleoli (black arrows) and in the cytosol of tumoral cells; staining for CD31 
(black arrows) reveals positive vessels; neo-angiogenesis is diminished both in eIF6 depleted conditions and upon drug administration. Scale bar is 
indicated. Data are represented as mean ± SD. Statistical p-values were calculated by two-tailed t-test (***p ≤ 0.001).
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findings according three lines, the relevance for malignant 
mesothelioma, the feasibility and significance to target 
eIF6, and the molecular mechanism which may account 
for the increased eIF6 expression in mesothelioma.
Malignant mesothelioma has three main 
morphological phenotypes, epithelial, sarcomatoid 
and biphasic. Most tumors arise in the pleura and are 
epidemiologically linked to asbestos exposure. However, 
peritoneal mesothelioma also occurs, it is very rare and 
does not correlate with asbestos exposure [28]. Malignant 
mesotheliomas originate, by contrast to other tumors, as 
polyclonal tumors [38]. Genetic analysis of abnormalities 
has scored an heterogeneous mutational landscape with 
three predominating lesions, NF2, BAP1 and CDKN2A 
[39]. miRNA expression is highly variable [40]. Thus, by 
all means MPM can be defined as a highly heterogeneous 
cancer. What is not heterogeneous is the (non) response 
to therapy. MPM is generally found to be resistant to 
conventional forms of therapy, such as pemetrexed and 
cisplatinum combination chemotherapy [41]. Thus, on one 
side, tumor heterogeneity is a major obstacle for applying 
targeted therapies to mesothelioma and on the other, 
conventional therapies do not work. Since the components 
of the translational apparatus integrate different oncogenic 
pathways, targeting the components of this machinery 
may overcome tumor heterogeneity. Moreover, malignant 
cells exhibit an increase of the translational machinery 
suggesting “addiction” to high protein synthesis [4]. The 
fact that eIF6 is hyperexpressed and hyperphosphorylated 
in “MPM” suggests it may be a good target.
There is substantial body of evidence that eIF6 is 
rate-limiting for cancer cells. First, overexpression of 
eIF6 is a driver of cancer. Enlargement of eIF6 containing 
nucleoli is a feature of aggressive colorectal tumors [26]. 
Soft agar assay of eIF6+/− mouse embryonic fibroblasts 
transduced with either dominant negative p53 tumor 
suppressor plus H-rasV12 or with Myc plus H-rasV12 
display a 70% reduction in transformed colonies, 
compared to the eIF6+/+ counterparts [20]. The tumorigenic 
potential of eIF6 is particularly striking in a mouse model 
of lymphomagenesis, in vivo. In this setting, expression 
of the Myc oncogene under the control of the enhancer 
of IgH (Eμ-Myc) in the B cell lineage drives a lethal 
lymphoma, similar to B-cell lymphomas, with a median 
survival of only 4 months. Eμ-Myc/ eIF6+/− mice have 
increased survival, up to 1 year and do not show overt 
negative phenotypes. Even in the p53−/− genotype, where 
p53 deletion further accelerates lymphomagenesis due 
to suppression of apoptosis [42], eIF6 depletion delays 
tumor development. In addition, eIF6 is amplified in 
breast luminal cancers [27]. The phosphorylation of 
Ser235 residue on eIF6 is necessary for transformation and 
cancer development. eIF6 is controlled by the RACK1/
PKCβ axis, allowing active 80S complex formation 
and leading to initiation of translation [23, 25, 43, 44]. 
PKCB is a pharmacological target in lymphomas [45], 
and is expressed in mesotheliomas [46]. We previously 
showed that inhibition of eIF6 phosphorylation by genetic 
inactivation of Ser235 is a way to block eIF6 activity [21, 
23, 32]. Since eIF6 phosphorylation is driven by the PKCβ 
axis, we decided to inhibit its activity with Enzastaurin 
(LY317615). Enzastaurin is a FDA approved potent and 
selective inhibitor of PKCβ; it exerts its antitumor effects 
both directly, by suppressing tumor cell proliferation and 
inducing apoptosis, and indirectly, by blocking tumor 
induced angiogenesis [33, 47–51]. Here we show that 
reducing eIF6 levels or treating cells with the PKCβ 
blocker Enzastaurin, restricts MPM cell line growth, in 
vitro, and tumor development and angiogenesis, in vivo, in 
an immunocompromised murine model. Caveats remain: 
Figure 6: Anti-Warburg effect: eIF6 depletion causes less Glycolysis and ATP content in REN cells. A. Seventy-two 
hours after lentiviral infection, REN cells are treated with Enzastaurin for 16 or 72 hours at indicated concentrations. Lactate secretion, an 
index of glycolytic flux, is significantly reduced in eIF6-depleted and in Enzastaurin-treated cells. B. ATP content depends on eIF6 levels 
and Enzastaurin treatment: acute depletion of eIF6 and Enzastaurin treatment lead to a reduction of ATP levels of REN cells. All values 
represent the mean ± SD. Results derive from three independent experiments. Asterisks indicate a statistically significant change obtained 
by Student t-test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).
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first, in the long run eIF6 inhibition by Enzastaurin may 
not be effective since eIF6 has multiple phosphorylation 
sites in its C-terminus [22], yet poorly characterized. 
Alternative strategies may be therefore required. Second, 
we have shown that eIF6 activity in cancer is necessary 
for dissociating inactive 80S subunits. In this context, 
several point mutations of eIF6 change the efficiency of 
eIF6 binding to 60S [52]. Recent work from our laboratory 
has led to the development of a powerful antiassociation 
assay which may be used for screening inhibitors of eIF6 
function, by small compounds chemical libraries. Similar 
approaches have been successful in targeting other 
translation factors like eIF4G [53].
Cancer cells alter and reprogram their metabolism 
to take advantage for growing and developing tumor. 
This alteration (Warburg phenomenon) consists of an 
increase in glycolysis that is maintained in conditions 
of high oxygen tension (“aerobic glycolysis”) and 
gives rise to enhanced lactate production and glycolytic 
ATP generation [54]. Moreover, as well as producing 
more energy, tumor cells increase lipids synthesis to 
build membranes during oncogenesis [55]. In our lab, 
we developed a transgenic mouse model where eIF6 
heterozygous mice had approximately 50% of reduction 
of eIF6 protein [20]. In this in vivo model, we recently 
found that eIF6 translational activity directs a lipogenic 
and glycolytic program through the regulation of enzymes 
involved in cholesterol and fatty acid synthesis as well 
as other transcription factors [37]. These data suggested 
that a similar event might occur in cancer cells, namely 
eIF6 favors a glycolytic switch. Here, we found that 
eIF6 depletion and its inactivation through Enzastaurin 
significantly impair lactate and ATP production in MPM 
cells. Therefore, our findings may at least partially explain 
Figure 7: Simplified graphical summary of eIF6 activity in Malignant Pleural Mesothelioma. Growth factors stimulation 
activates PLCγ enzyme, which catalyzes DAG formation, and induces Ca2+ release from Endoplasmic Reticulum into the cytoplasm. DAG, 
in the presence of Calcium, activates PKCβII. The latter phosphorylates eIF6, leading to its release from mature 60S ribosomal subunit. 
eIF6 activation allows 80S complex assembly and initiation of translation. PMA and Enzastaurin are able to stimulate or inhibit respectively, 
PKCβ kinase activity. The translational rate increases during tumorigenesis. eIF6 protein levels and its activity could modulate protein 
synthesis, metabolic status and cell growth: in MPM, contribution of both eIF6 hyperexpression and eIF6 hyperphosphorylation promotes 
protein synthesis, aerobic glycolysis (metabolic switch) and uncontrolled cellular growth, giving rise to tumor development and malignancy.
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the anti-cancer role of eIF6 inhibition in vivo. Our data are 
in agreement with the observation that mutation of eIF6 
Ser235 to Ala greatly reduces cancer growth in vivo, more 
efficiently than in vitro. Since the effects of eIF6 depletion 
on polysomal accumulation are significant, but modest, 
we expect that specific mRNAs might be regulated by 
eIF6 activity, at the translational level in REN cells. It 
will be therefore interesting to apply to mesothelioma 
tissues novel technologies as ribosome profiling, in order 
to isolate them [56].
In conclusion, we suggest that modulation of eIF6 
levels and activity may lead to a therapeutical avenue 
in tumor therapy, especially where eIF4E inhibition by 
rapalogs is not effective, as in malignant mesothelioma 
[29, 30].
MATERIALS AND METHODS
Mice
All experiments involving mice were performed in 
accordance with italian national regulations. Experimental 
protocols were reviewed by local Institutional Animal 
Care and Use Committees (IACUC form sk481). Eight-
week old immunocompromised NOD-SCID mice (Charles 
River Laboratories) were used for detecting tumor growth 
after intraperitoneal (i.p.) injection of REN cells, as 
indicated. REN growth, in vivo, is modest [57]. Tumor 
growth was monitored and animals were sacrificed at 
maximal survival time, settled at 60 days post-injection.
Cell lines and lentiviral vectors
For this study we used different MPM cell lines: 
REN cells for Epithelioid subtype, MM98 for Sarcomatous 
subtype and MSTO-211H for Biphasic subtype. Met-5A 
(ATCC® CRL-9444™) are immortalized non-tumorigenic 
mesothelial cells. REN and MM98 cells were grown in 
DMEM (Lonza), MSTO-211H were grown in RPMI1640 
(Lonza) and Met-5A cells in Medium 199 (Life Tech). All 
media were supplemented with 10% FBS and 1% penicillin, 
streptomycin, L-glutamine, and all cells were maintained 
at 37°C and 5% CO2. For Western Blotting analysis, 
normal human primary mesothelial cells were used as Non-
Tumoral control. Cells were purchased from Cambridge 
Bioscience (Cambridge, UK) and maintained according to 
manufacturer instructions, up to 3 passages. Densitometric 
analysis was performed by ImageJ software.
MPM cells were stably infected with either 
one constitutive lentiviral vector carrying scramble 
ShRNA, used as control, or one carrying eIF6 ShRNA. 
Lentiviral vectors, pGIPZ Lentiviral ShRNA, were 
provided by Open Biosystem. Specifically, mature 
antisense sequences of consitutive shRNA of eIF6 were: 
5′-AGCTTCCTACTAGCACCTG-3′ (V3LMM_421640; 
GIPZ eIF6 shRNA: RMM4532-EG16418). After lentiviral 
infection, REN cells were selected with puromycin 
(1 μg/ml) for 48 hours, expanded and treated for with 
Enzastaurin as specifically described. Similar results are 
seen using other eIF6 shRNAs as in [37].
Antibodies and reagents
The following antibodies were used: rabbit 
polyclonal antibodies against eIF6 [58], rpS6, phospho-
rpS6 (Ser240/244), total 4EBP1 (Cell Signaling), 
P-PKCβII (Cell Signaling); anti-PKCβII (Santa Cruz); 
rabbit polyclonal anti-VEGFA (Abcam); mouse 
monoclonal antibodies against β-Actin (Sigma), PKCβ 
(BD-Bioscience) RACK1 IgM (BD Transduction 
Laboratories). Biotin was obtained from Pierce, 
EuroClone (EZ-LINK NHS-LC-BIOTIN). Lambda 
Protein Phosphatase (Lambda PP) was provided by NEB. 
Enzastaurin was provided by Eli Lilly and Company 
(Indianapolis, USA). eIF6 recombinant protein was 
produced in E. Coli by simultaneous co-expression with 
chaperones [21], followed by affinity chromatography and 
size exclusion chromatography (SEC; GE Healthcare).
mRNA extraction and real-time RT–PCR
Total RNA was extracted with TRIzol reagent 
(Invitrogen). After treatment of total RNA with RQ1 
RNase-free DNase (Promega), reverse transcription was 
performed with MMLV reverse transcriptase enzyme 
(Promega) according to the manufacturer’s instructions. 
Reverse transcribed complementary DNA (100 ng) 
was amplified with the appropriate primers. Taqman 
probes specific for eIF6 (Hs00158272_m1) and 18S 
rRNA as an internal standard, were used. Target mRNA 
quantification by quantitative reverse-transcriptase PCR 
using ∆∆Ct-method using Taqman Universal PCR 
Master Mix (4304437; Life Technologies) was performed 
on an ABIPRISM 7900HT Sequence Detection System 
(Applied Biosystems). Results are represented as means 
± SD of at least three independent experiments.
Cell proliferation, cell cycle and cell death analysis
Proliferation rate of MPM cells was analysed by 
MTT test: briefly, cells were plated in 96 wells plates 
at different concentrations, and assayed after 24, 48 
and 72 hours. MTT (3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide) was added and left on 
cells for 3 hours at 37°C and 5% CO2. The resulting 
intracellular purple formazan was solubilized with SDS 
and quantified by spectrophotometer at λ = 550/650 nm. 
Cell cycle analysis was performed on G1 synchronized 
REN cells. Cells were starved in DMEM without FBS for 
12 hours, and then in PBS plus 0,5 mM MgCl2, 10 mM 
D-Glucose, 1 mM CaCl2 for 3 hours. At the indicated time 
points, cells were fixed, stained with propidium iodide (PI) 
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and acquired on a BD FACS CANTO II flow cytometer. 
Cell cycle analysis was performed using the FCS Express 
software (BD). Cell death detection was performed using 
APC-Annexin V (BioLegend). Each experiment was done 
at least in triplicate.
Polysomal profiles
Growing cells were lysed using a glass douncer in 
50 mM Tris HCl pH 7.8, 240 mM KCl, 10 mM MgSO4, 
5 mM DTT, 250 mM sucrose, 2% Triton X-100, 90 μg/
ml cicloheximide, 30 U/ml RNasin. Following clearing, 
the equivalent of two-hundreds micrograms of RNA was 
loaded on a 15%–50% sucrose gradient dissolved in 
25 mM Tris HCl pH 7.4, 25 mM NaCl, 5 mM MgCl2, 
1 mM DTT and spun at 260,000 g for 3 h 30 min with 
SW41Ti swing rotor (Beckman Coulter). The gradient 
was then analyzed by continuous flow absorbance at 254 
nm, recorded by BioLogic LP software (BioRad). Peaks 
for 40S, 60S, 80S and polysomes were quantified. For 
dissociation studies, total extracts of REN cells were 
incubated 2 minutes at 37°C, with 5 μg of recombinant 
eIF6 protein or matched controls (PBS; denatured 
protein), and separated on a 7%–45% sucrose gradient. 
Extracts containing up to 200 micrograms of RNA were 
loaded on a 7%–45% (w/v) sucrose gradient containing 
50 mM Tris-acetate pH 7.5, 50 mM NH4Cl, 12 mM 
MgCl2 and 1 mM DTT, and centrifuged in a Beckman 
SW41 Ti rotor for 3 h 30 min at 260,000 g. The gradient 
was analyzed as above. In addition, individual fractions 
were collected. Fractions were precipitated with 10% 
trichloroacetic acid (TCA) [23], separated on SDS-PAGE 
and analyzed by Western blot.
Datamining
Datasets were retrieved by GEO databases. The 
affy package was then used to carry out RMA based 
normalization. Quantitation of target genes was performed 
by setting expression thresholds at upper one/third. 
Calculation was performed as follows: original set of 
microarray data was retrieved from GSE2549. The dataset 
contains 54 MMP patients. Samples without follow-up 
survival were discarded, obtaining 42 patients. Expression 
data on eIF6 and PRKCB were retrieved. Retrieved values 
ranged for eIF6 from 106 (min) to 468 (max), and for 
PRKCB from 62 (min) to 403 (max). Assuming that eIF6 
hyperphosphorylation and overexpression were linked, 
we calculated the combined expression by multiplying 
the eIF6 × PRKCB values. Samples which gave a result 
in the first quartile of combined expression (practically 
with values above 1.5 fold the average expression of eIF6 
and PRKCB) were compared to the others with the null 
hypothesis that combined eIF6-PRKCB expression had no 
effect on survival. Statistical analysis was performed by a 
paired t-test.
Immunohistochemistry
Immunohistochemical and histological analysis 
were performed on paraffine-embedded human 
mesothelioma tissues. Immunoistochemistry (IHC) for 
eIF6 and calretinin were done using the Vectastain Elite 
ABC kit (Vector), as previously described [20, 26, 28]. 
Some sections were counterstained with Hematoxylin-
Eosin (H&E).
Two-dimensional (2-D) gel electrophoresis
Protein extracts of REN, Met-5A and tumor 
samples, in all described conditions were examined in 
2-D gel electrophoresis. Samples were lysed in SDS-free 
RIPA buffer and proteins were precipitated with 10% 
TCA. Pellets were resuspended in 2-D buffer (7 M Urea, 
2 M Thiourea, 50 mM DTT and 4% CHAPS) and 100 μg 
of proteins were isoelectrofocused. The first dimension 
was performed on Ready Strip IPG (pH 3.9–5.1; Biorad). 
For the reduction/alkylation step, the strips were incubated 
with re-equlibration buffer (50 mM Tris-HCl, pH 8.8, 6 M 
urea, 30% glycerol, 2% SDS, bromophenol blue) plus 
DTT and re-equilibration buffer plus iodoacetamide, 
respectively. Then, the strips were subjected to SDS/PAGE 
for the second dimension. Proteins were transferred on 
PVDF membrane and subsequently incubated with eIF6 
monoclonal antibodies [21]. The signal was detected with 
an anti-mouse secondary antibody and ECL substrate kit 
(GE Healthcare). Each experimental sample was run at 
least twice, and at least three different biological replicates 
were analyzed.
Measurements of lactate secretion and ATP content
REN cells were plated at 2 × 105 cells/well in 12-
well dishes in high-glucose medium for 24 hr [59]. Cells 
were switched to serum-free high-glucose (4,5 g/L)/high 
insulin (100 nM) medium for 4 hr. Lactate secreted into the 
medium was measured using a fluorogenic assay, Lactate 
Assay Kit (Biovision). Average of fluorescent intensity 
was calculated for each condition replicates. Values were 
normalized to protein content obtained from the same 
wells. For ATP measurements, samples were homogenized 
in ice-cold ATP buffer (20 mM Tris, pH 7.5, 0.5% Nonidet 
P-40, 25 mM NaCl, 2.5 mM EDTA) for 5 min. Lysates 
were centrifuged at 13,000 g for 30 min. Proteins were 
quantitated by BCA analysis. Luminometric determination 
of ATP was assayed using the ATP-determination kit 
(Molecular Probes) according to [60].
Statistical analysis
Each experiment was repeated at least three times, 
as biological replicates; means and standard deviations 
between different experiments were calculated. Statistical 
p-values obtained by Student t-test were indicated: three 
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asterisks *** for p-values less than 0.001, two asterisks ** 
for p-values less than 0.01 and one asterisk * for p-values 
less than 0.05.
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